Liang‐Yi Si

837 citations
29 papers · 661 indexed · h-index 15
Topics
Parathyroid Disorders and Treatments (3 papers)Calcium signaling and nucleotide metabolism (3 papers)Antiplatelet Therapy and Cardiovascular Diseases (3 papers)
Partner nations
ChinaUnited States

In The Last Decade

Liang‐Yi Si

27 papers receiving 648 citations

Peers

Liang‐Yi Si
Comparison fields: 5 of 91
  • Molecular Biology 178
  • Physiology 170
  • Cardiology and Cardiovascular Medicine 99
  • Pulmonary and Respiratory Medicine 87
  • Epidemiology 77
Replace Yaoyuan Zhang with:
Yaoyuan Zhang China
Mohamed Amine Zaoualí Tunisia
Wencheng Di China
Marjut Louhelainen Finland
Lin Xiao China
Ayliz Velioğlu‐Öğünç Türkiye
Manling Liu China
Motoaki Komatsu Japan
Yibing Lu China
Liang‐Yi Si relative to Yaoyuan Zhang China Yaoyuan Zhang's profile →
Citations per field
00.5×10×15×20.7×
Yaoyuan Zhang · 1×
Citations per year

Countries citing papers authored by Liang‐Yi Si

Since Specialization
Citations

This map shows the geographic impact of Liang‐Yi Si's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liang‐Yi Si with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liang‐Yi Si more than expected).

Fields of papers citing papers by Liang‐Yi Si

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liang‐Yi Si. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liang‐Yi Si. The network helps show where Liang‐Yi Si may publish in the future.

Co-authorship network of co-authors of Liang‐Yi Si

This figure shows the co-authorship network connecting the top 25 collaborators of Liang‐Yi Si. A scholar is included among the top collaborators of Liang‐Yi Si based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liang‐Yi Si. Liang‐Yi Si is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 10
3 8
4 23
5 6
6 66
7 32
8 22
9 2
10 3
11 17
12 37
13 72
14 14
15 30
16 35
17 56
18 44
19 7
20 44

About Liang‐Yi Si

Liang‐Yi Si is a scholar working on Physiology, Nephrology and Geriatrics and Gerontology, having authored 29 papers that have together received 661 indexed citations. Recurring topics across this work include Parathyroid Disorders and Treatments (3 papers), Calcium signaling and nucleotide metabolism (3 papers) and Antiplatelet Therapy and Cardiovascular Diseases (3 papers). The work is most often cited by research in Geriatrics and Gerontology (61 citations), Physiology (45 citations) and Nephrology (70 citations). Liang‐Yi Si has collaborated with scholars based in China and United States. Frequent co-authors include Qiang Xu, Wang Zhang, Qiang Xu, Qihong Yang, Hang Xiao, Xuejun Li, Qiao‐Ying Yuan, Fan Yang, Jun Long and Gang Tang. Their work appears in journals such as Journal of Biological Chemistry, PLoS ONE and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026